Prominent Players in India Ozempic Market | Growth Insights 2026

Prominent Players in India Ozempic Market

India Ozempic market is experiencing a profound structural transformation as domestic manufacturing capabilities and biosimilar development accelerate to meet the surging demand for GLP-1 therapies. This transition is being pushed by a combination of established pharmaceutical clusters and world-leading biosimilar innovators, all vying for market share through enhanced peptide synthesis, reusable delivery devices, and the adoption of integrated digital patient-support ecosystems. Major market players include Novo Nordisk, Sun Pharma, Zydus Lifesciences, and Dr. Reddy’s Laboratories.

India Ozempic Market Overview

According to 6Wresearch, the India Ozempic market is marked for steady expansion as the country's healthcare sector increasingly prioritizes accessible obesity and type 2 diabetes management. Semaglutide, which involves the complex manufacturing of GLP-1 receptor agonists, is commonly used to address the rising burden of metabolic disorders across diverse socioeconomic segments. In general, the market is an evolving ecosystem that utilizes large-scale fermentation, advanced fill-finish facilities, and widespread pharmacy networks to deliver life-changing treatments to millions of patients.

Competitive Landscape

The competitive landscape of the India Ozempic market is characterized by the presence of several established global innovators, high-capacity domestic manufacturers, and a growing number of strategic marketing alliances. Moreover, significant investment in research and development (R&D) to innovate and create cost-effective oral formulations and simplified injection pens has surged in order to cater to the increasing consumer demand for affordable, high-efficacy weight-management solutions following recent patent expirations.

Below is a list of key players operating in the India Ozempic Market:

1. Novo Nordisk A/S

The global innovator behind Ozempic, maintaining a premium market presence through its original FlexTouch delivery system and established clinical trust.

2. Sun Pharmaceutical Industries

India’s largest drugmaker, leading the generic wave with its brands Noveltreat and Sematrinity for weight management and diabetes.

3. Zydus Lifesciences

A pioneer in biotech innovation, offering generic semaglutide via its unique reusable pen device under brand names like Semaglyn and Mashema.

4. Dr. Reddy’s Laboratories

Focuses on "Obeda," its injectable semaglutide, alongside an integrated care ecosystem including dedicated metabolic clinics for patient support.

5. Eli Lilly and Company

A primary competitor in the metabolic space, marketing Mounjaro (tirzepatide) as a high-efficacy alternative to traditional semaglutide therapies.

6. Torrent Pharmaceuticals

Distinguished as a first-mover in the oral semaglutide segment, providing patient-friendly tablet options under the brand Sembolic.

7. Lupin Limited

Operates through strategic licensing agreements to market high-quality semaglutide injections, leveraging its massive domestic distribution reach.

8. Alkem Laboratories

A major disruptor in the market, utilizing an aggressive pricing strategy and reusable pens to increase affordability for the mass market.

9. Glenmark Pharmaceuticals

Launched "GLIPIQ," providing injectable semaglutide in both vial and pen formats to cater to diverse clinical and economic requirements.

10. Natco Pharma

Targets the most price-sensitive market segments by offering low-cost vial formats, significantly lowering the entry barrier for treatment.

11. Eris Lifesciences

Focuses on the "Sundae" brand of semaglutide vials, utilizing strong partnerships to ensure reliable supply across its chronic care portfolio.

12. Cipla Limited

A global respiratory and chronic care leader currently expanding its metabolic pipeline to include affordable peptide-based weight-loss solutions.

13. Mankind Pharma

Leverages its extensive rural and semi-urban reach to prepare for the large-scale distribution of affordable anti-obesity medications.

14. Biocon Limited

A world-class biopharmaceutical innovator focused on complex generics and biologics, positioning itself for global and domestic semaglutide supply.

15. USV Private Limited

A leader in the Indian diabetes market, utilizing specialized marketing tie-ups to deliver advanced GLP-1 therapies to its established patient base.

Prominent Players in India Ozempic Market: FAQs